Navigation For Mobile
  2. >
  3. Blog
  4. >
  5. outsourcing
  6. >
  7. Page 2

Category Archives: outsourcing

Speed-to-Market: Streamlining Pharma API Production

Posted on December 3, 2017 by

In both the generic and innovator pharmaceutical API production sectors, time-to-market is a critical factor. How critical? A one-day delay in reaching the market could mean the loss of $1…

Posted in API synthesis, APIs, Capabilities, Chemistry, Contract Manufacturing, CRO/CMO, drugs, method development, Neuland Labs, outsourcing, Paragraph IV, process chemistry, Process Engineering, speed-to-market, time-to-market | Comments Off on Speed-to-Market: Streamlining Pharma API Production

Defining the Contract Pharma Provider Relationship

Posted on June 18, 2017 by

I read an article at Pharmaceutical Manufacturing earlier this year (Inking the Deal: Mastering the art of lasting outsourcing relationships in the pharmaceutical industry) on the nature of contract pharma…

Posted in agreement, APIs, Contract Manufacturing, drugs, method development, Neuland Labs, outsourcing, process chemistry, Process Engineering, Project Management | Comments Off on Defining the Contract Pharma Provider Relationship

The Outsized Impact of Smaller Pharma CDMOs

Posted on January 22, 2017 by

One portion of an article at PharmTech (Five Themes That Will Drive the CMO Industry) discussing opportunities for smaller CMOs recently caught my eye. It mentioned that those aforementioned opportunities…

Posted in Capabilities, CDMO, Contract Manufacturing, CRO/CMO, Neuland Labs, outsourcing, process chemistry, QA/QC, Quality, R&D, regulatory, scale-up | Comments Off on The Outsized Impact of Smaller Pharma CDMOs

Quality by Design: Essential, Not Optional

Posted on January 8, 2017 by

In today’s pharmaceutical industry, Quality by Design (QbD) has become an essential – instead of optional – tool. In fact, the phrase, “essential instead of optional” reminds me of the…

Posted in API synthesis, APIs, Chemistry, CMC, FDA, Neuland Labs, outsourcing, QbD, Quality, regulatory | Comments Off on Quality by Design: Essential, Not Optional

Pharma APIs and India’s National Security

Posted on December 18, 2016 by

I’m not usually given to using clickbait-type headlines that scream “the sky is falling!”, but I came across a recent article which is a bit eye-opening for our domestic drug…

Posted in APIs, Capabilities, Chemistry, CRO/CMO, Neuland Labs, outsourcing | Comments Off on Pharma APIs and India’s National Security

Moving Towards Specialty APIs

Posted on May 15, 2016 by

In a recent issue of PharmTech, Agnes Shanley wrote an article on the specialty markets and services driving the growth of APIs in which we were featured. For me, the…

Posted in API synthesis, Capabilities, Chemistry, CMC, Contract Manufacturing, CRO/CMO, Neuland Labs, outsourcing, Pharm Tech, Pharmaceutical Technology, QbD, Quality | Comments Off on Moving Towards Specialty APIs

The Pharma Capacity Crunch: CMOs/CRAMs Crucial to Strategic Capacity Planning for Pharma and Biotech

Posted on October 4, 2015 by

The continued growth of virtual pharma – and the subsequent rise of virtual biotech – have made a lasting impression on the pharmaceutical contract manufacturing industry. Big Pharma firms, some…

Posted in API synthesis, APIs, Capabilities, Contract Manufacturing, CRO/CMO, outsourcing | Comments Off on The Pharma Capacity Crunch: CMOs/CRAMs Crucial to Strategic Capacity Planning for Pharma and Biotech